Orris

Immune thrombocytopenia

Reading File
Reading File
Finding Sources
Finding Sources
Searching PubMed

"immune thrombocytopenia" AND treatment

Searching the Web

immune thrombocytopenia guideline diagnosis treatment American Society of Hematology

Reading File
Reading File
Reading Web Page

https://www.hematology.org/education/clinicians/guidelines-a…

Finding Sources
Finding Sources
Reading Article

PMID: 41017452

Reading Web Page

https://doi.org/10.1182/bloodadvances.2026021269

Immune thrombocytopenia (ITP)

ITP is an acquired autoimmune disorder in which antibodies and immune-cell activity cause increased platelet destruction and reduced platelet production. It usually presents as isolated thrombocytopenia, meaning a low platelet count with otherwise no clear abnormality in the blood count or smear.

Types

  • Primary ITP: no underlying cause identified.
  • Secondary ITP: associated with another condition, such as SLE, HIV, hepatitis C, lymphoproliferative disease, H. pylori, or certain drugs.
  • By duration:
    • Newly diagnosed: <3 months
    • Persistent: 3-12 months
    • Chronic: >12 months
    • Rosen's Emergency Medicine, p. 2470

Clinical features

  • Often asymptomatic.
  • Petechiae, purpura, easy bruising
  • Epistaxis, gum bleeding, heavy menstrual bleeding
  • Gastrointestinal or intracranial hemorrhage is uncommon but potentially life-threatening.
  • There is generally no splenomegaly or lymphadenopathy in primary ITP. Their presence should prompt evaluation for another diagnosis.

Diagnosis

ITP is a diagnosis of exclusion. A platelet count <100,000/µL is generally used as the diagnostic threshold, but the clinical context matters.
Goldman-Cecil Medicine, p. 1795
Key evaluation:
  • Repeat CBC and examine the peripheral smear to exclude platelet clumping, blasts, schistocytes, or other cytopenias.
  • Review medications and alcohol use.
  • Test for secondary causes when appropriate, commonly HIV, hepatitis C, and autoimmune disease.
  • Bone marrow examination is not routinely required for typical isolated ITP, but is considered if atypical features suggest marrow disease or another diagnosis.
Important differentials: pseudothrombocytopenia, drug-induced thrombocytopenia, thrombotic thrombocytopenic purpura, DIC, infection/sepsis, marrow failure or leukemia, hypersplenism, and liver disease.

When to treat

Treatment is based mainly on bleeding risk, platelet count, age, comorbidities, anticoagulant or antiplatelet use, and planned procedures, rather than the platelet count alone.
Observation is often appropriate for adults with no or only minor bleeding and a platelet count around or above 30 × 10⁹/L, with hematology follow-up.

Treatment

First-line
  • Corticosteroids:
    • prednisone-based short course, or
    • dexamethasone pulse therapy.
  • IVIG when a rapid platelet rise is needed, such as significant mucosal bleeding, a needed urgent procedure, or very low platelet count.
  • Anti-D immunoglobulin may be an option in selected Rh-positive, nonsplenectomized patients.
The current 2026 ASH adult ITP guideline conditionally supports initial rituximab plus corticosteroids or a thrombopoietic agent plus corticosteroids, rather than corticosteroids alone, for adults with primary ITP. Choice should reflect bleeding risk, need for rapid response, adverse effects, convenience, and patient preference.
Second-line or persistent/chronic ITP
  • Thrombopoietin receptor agonists (TPO-RAs): eltrombopag, romiplostim, avatrombopag
  • Rituximab
  • Fostamatinib
  • Splenectomy, usually delayed where possible and considered after discussing long-term infection and thrombosis risks.
The 2026 ASH guideline makes a strong recommendation for a thrombopoietic agent after failure of first-line corticosteroids; rituximab is another conditional option. A recent systematic review and network meta-analysis of 29 RCTs found that several second-line agents are effective, but comparison is indirect and treatment must still be individualized (Zhou et al., 2026, PMID 41017452).

Emergency management

Major bleeding, suspected intracranial bleeding, or hemodynamic instability requires emergency assessment. Typical urgent management includes:
  • high-dose corticosteroids
  • IVIG
  • platelet transfusion for critical bleeding, generally alongside IVIG and steroids because transfused platelets may be rapidly destroyed
  • urgent hematology involvement and treatment of the bleeding site/cause.
For severe thrombocytopenia (<5,000/µL) or internal bleeding, Goldman-Cecil advises pulse corticosteroids plus IVIG, with platelet transfusion concurrently with IVIG for critical bleeding.
Goldman-Cecil Medicine, p. 1812

Practical precautions

Until reviewed by a clinician:
  • Avoid aspirin, ibuprofen, naproxen, and other NSAIDs unless specifically advised.
  • Avoid contact sports and activities with substantial head-injury risk if counts are very low.
  • Seek urgent care for severe headache, confusion, weakness, blood in stool or urine, vomiting blood, uncontrolled bleeding, or unusually heavy menstrual bleeding.
ITP needs individualized assessment, particularly in pregnancy, children, older adults, people taking anticoagulants, and anyone with bleeding symptoms.
This is a shared conversation. Sign in to Orris to start your own chat.